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Abstract
Pancreatic adenocarcinoma is one of the most lethal malignancies among solid tumors. 
Unfortunately, several patients are diagnosed at metastatic stage or with unresectable dis-
ease due to vascular compromise involving the pancreas without any chance of curative 
treatment. There are also two other groups of patients: resectable patients at upfront diagno-
sis and “borderline resectable” pancreatic cancer patients. This last group represents those 
patients where surgery is not always possible without a preoperative treatment allowing 
surgeons to perform an R0 resection. Achieving an R0 resection is the only curative option 
for pancreatic cancer patients; nevertheless, many R0-resected patients will relapse within 2 
years from surgery. Despite adjuvant treatment, reported median overall survival is only 28 
months for patients with resectable pancreatic adenocarcinoma; thus, neoadjuvant treatment 
has been explored in order to improve survival. We aim to describe the controversial reported 
data and to show the recommendations that are suggested for these patients; however, we 
need to remark that there is no strong data that support neoadjuvant treatment. Currently, 
clinical trials are ongoing, and probably soon this approach will become a standard of care 
among borderline resectable patients and probably in selected resectable patients too.
Keywords: neoadjuvant treatment, pancreas cancer, borderline resectable pancreatic 
cancer
1. Introduction
Pancreatic cancer is one of the most lethal malignancies among all types of solid tumors. 
Most of the patients are diagnosed at clinical and radiological late stages when curative 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
treatments are no feasible to perform. To date, surgical resection is still the only potential 
curative treatment for the adenocarcinoma of the pancreas; however, only 15–20% of all 
the newly diagnosed patients will be candidates for curative pancreatectomy as an upfront 
treatment.
A complete radiological evaluation defines three subtypes of patients: metastatic and/or 
unresectable patients, resectable patients, and borderline resectable patients. This last group 
includes patients with vascular tumor compromise that could become resectable after an ade-
quate neoadjuvant treatment.
The prognosis of the pancreatic cancer is poor, even in those patients with resectable disease 
who underwent oncological surgery and adjuvant treatments if they were recommended, but 
also for those patients with borderline resectable disease who achieved oncological resection 
after neoadjuvant treatment that may include chemotherapy, radiotherapy, or a combination 
of both. Despite an optimal treatment, many of the resected patients will relapse within the 
24 months after completing adjuvant treatment or after surgery. The 5-year survival follow-
ing pancreaticoduodenectomy is only 25–30% for node-negative and 10% for node-positive 
tumors. The need to improve these results has led us to the development of new treatment 
strategies that will be discussed ahead in this chapter.
2. Epidemiology of the adenocarcinoma of the pancreas
As mentioned earlier, pancreatic adenocarcinoma is one of the malignancies with worse 
prognosis among all solid tumors, with a small number of patients who will achieve cure 
after an optimal treatment, only if they have access to a good quality of cancer therapies 
based on specialized oncological surgeons who usually perform pancreas cancer surgery. 
In the United States, pancreatic cancer is the second most common malignant tumor of the 
gastrointestinal tract and the fourth malignancy related to cancer death in adults [1], with 
an estimated incidence of 48,960 new cases by 2015 and 40,560 deaths during the same year. 
Reported incidence and mortality are slightly higher in men than in women [2]. According 
to the reports of “Surveillance, Epidemiology and End Results Program” (SEER), the inci-
dence of pancreatic adenocarcinoma is greater in males than in females (male-to-female ratio 
1.3:1) and in Afro American population than in white population (14.8 per 100,000 in Afro 
American males compared with 8.8 per 100,000 in the general population) [3]. Worldwide, 
pancreatic cancer is the eighth leading cause of death related to cancer in men (138,100 
deaths per year) and the ninth cause of death related to cancer among female population 
(per year) [4].
In some developing Latin American countries, for reasons associated with industrialization 
and with the increasing life expectancy, pancreatic cancer and biliary tract malignancies 
are becoming more frequent diseases in adult population regardless of the educational and 
socioeconomical level. As an example, in Chile, one of the most developed countries in South 
America, with an estimated population of almost 17 million inhabitants, the reported annual 
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mortality rate for pancreatic adenocarcinoma was 5.8 for 100,000 in men and 5.6 for 100,000 in 
women by 2012. Curiously, due to problems with the cancer registries in Chile as in other 
countries of the region, the reported mortality may be higher than the reported incidence for 
this malignancy during the same period [5]. Despite the lack of better cancer registries, it is 
well known that the incidence and mortality rates are similar among patients with pancre-
atic cancer, and both curves get closer in low- and middle-income countries; nevertheless, in 
developed countries, the chance of surviving a pancreatic cancer is still low and the incidence 
rate is just a little higher than the mortality rate.
Assuming a correct diagnosis and a complete staging, there are different rates of mortality 
among pancreatic cancer patients according to the extension and probability of resection of 
the whole tumor. The 5-year survival for all the patients is 7.2%. The highest survival is found 
in 27.1% with very localized disease, but this rate dramatically decreases up to 10.7% for 
regional disease, and for metastatic disease, the 5-year survival is almost anecdotic with less 
than 2.5% of survival patients in that space of time [3].
3. Molecular biology and genetics
Several attempts looking for driver mutations and for trying to find target therapies to control 
pancreatic cancer spread have been made. Unfortunately, despite all the efforts, researchers 
have not conducted positive results in the clinical field, or at least their impact has not been 
relevant. Driver mutations such as KRAS, CDKN2A, TP53, and SMAD 4 have been involved 
in pancreatic cancer tumorigenesis [6], but without any impact on patients’ selection of treat-
ment yet. In other side, current immunotherapies that have achieved a great impact in the 
treatment of malignancies such as melanoma, lung cancer, bladder cancer, and others were 
not able to show benefit when tested in pancreatic cancer patients [7].
It is estimated that only 4–16% of pancreatic adenocarcinoma has a family history of this 
disease [8], while the rest of the cases may be considered as sporadic. To have a first-degree 
relative with an apparently sporadic pancreatic cancer has a moderate effect on the risk 
to develop this disease (odds ratio (OR), 1.76; 95% confidence interval (CI), 1.19–2.61) [9]. 
Selective mutations that have a recognized role in ovarian and breast cancer such as BRCA2 
and, in a lesser degree, BRCA1 have been associated with familial pancreas cancer [10]. As 
previously mentioned, there are other selected genes that may have been associated with 
pancreatic cancer, for example, PALB2 [11], CDKN2A [12], and SMAD4 [13]. There are also 
genetic syndromes linked to pancreas cancer (e.g., hereditary pancreatitis, HNPCC, familial 
breast cancer with BRCA2 mutations, p16 mutations, Peutz-Jeghers syndrome, ataxia telan-
giectasia) [14]. Routine genetic testing for patients with newly diagnosed pancreatic cancer is 
controversial but it could give some clinical benefit by reducing the risk of associated cancers 
and by identifying family members of the index case who might benefit from screening for 
the cancer-predisposing mutation. Nevertheless, this is not considered a standard practice by 
current guidelines [15].




For patients with tumors that appear resectable during the baseline staging, based on tomog-
raphy of the abdomen with pancreatic phase, which together represent probably only the 
20% of all pancreatic cancers, surgery remains the only potentially curative treatment option 
[16, 17]. The conventional surgical procedure for pancreatic cancer of the head and or the 
uncinate process is the pancreaticoduodenectomy. Conventional pancreaticoduodenectomy 
(i.e., Whipple procedure) involves removal of the pancreatic head, duodenum, the first 15 cm 
of the jejunum, common bile duct, gallbladder, and a partial gastrectomy [18]. Many times, 
despite a good quality of the surgery and adequate adjuvant treatments, pancreatic cancer 
has recurrences that will not be able to be treated with a curative intention. Complete R0 
resections have a high incidence of recurrence before 2 years after surgery [17], R1 and R2 
resections will have a higher and faster incidence of recurrence and in general should not be 
considered as patients who underwent a curative surgery. Among patients who underwent 
an R0 surgery, 75% of them will have a recurrence due to microscopic metastatic disease that 
was undetectable at diagnosis, or due to resistance of locoregional residual tumor cells to 
adjuvant treatments that include adjuvant chemotherapy, adjuvant radiotherapy, or chemo-
radiation. Most of the patients who did not achieve a complete resection will relapse with a 
recurrence rate very close to 100% [19, 20].
At the time of taking decisions to define resectability of pancreatic tumors, a multidisci-
plinary approach, including surgeons who have expertise in pancreatic tumor resection, 
medical oncologists, radio- oncologists, and well-qualified radiologists should be manda-
tory. With the support of specialized radiologists and the rest of the team as well, surgeons 
will be able to define if the patients may undergo a surgery as an upfront treatment or if 
they are definitely unresectable (including locally advanced unresectable disease and meta-
static disease).
A third group will be considered as “borderline” resectable patients. “Borderline resect-
able” definition is variable and somehow imprecise. As a global conception of this definition, 
we might consider that borderline pancreatic cancer involves those patients who, based on 
images and on oncological surgery team expertise, are not considered as unresectable but at 
the same time are not clearly resectable as an upfront treatment but could became resectable 
after a neoadjuvant treatment.
Some reserve the term “borderline resectable” for cases where there is focal (less than one-half 
of the circumference) tumor abutment of the visceral arteries or short-segment occlusion of 
the superior mesenteric vein or portal vein confluence. Others suggest that venous narrowing 
without occlusion should be included in the definition of borderline resectable disease [21]. 
Due to that, the aim of surgery in pancreatic cancer is to achieve an RO resection to give the 
chance of a curative treatment; borderline resectable patients are the best candidates to be 
treated with neoadjuvant therapies, and most of the time they should not undergo surgery 
as a first treatment due to a higher risk of not achieving a complete resection resulting in a 
potential negative impact in survival.
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5. Adjuvant therapy in pancreatic adenocarcinoma
Until recently, gemcitabine chemotherapy was the standard of care as adjuvant treatment in 
complete resected pancreatic cancer patients [22]. The use of radiation therapy or chemora-
diation has been controversial, without clear data to support its use among complete resected 
patients [23, 24]; however, there are groups that considered its use [25] mainly in the group of 
R1-resected patients and or among node-positive patients. It is important to remark that most 
of the recurrences will be distant metastasis and only a small percentage of patients will die 
due to local recurrence or due to local progression after resection; therefore, systemic treat-
ments should always be considered unless a clear justification for local regional treatment has 
been made.
Since 2017, the standard of care for early stage, resectable pancreatic adenocarcinoma patients 
is surgery followed by adjuvant chemotherapy combination of gemcitabine plus capecitabine 
according to ESPAC-4 trial. The median overall survival for these patients in the gemcitabine 
plus capecitabine group was 28.0 months (95% CI, 23.5–31.5) compared with 25.5 months 
(22.7–27.9) in the gemcitabine group (hazard ratio (HR) 0.82 (95% CI, 0.68–0.98), p = 0.032). 
Reported results showed a positive impact for the adjuvant therapy in most of the clinical 
subgroups, including patients with R1 resection margins [26].
S-1 is an oral 5 FU prodrug that has been tested in several malignancies with good results but 
with a limited efficacy among Asian population. In the phase III JASPAC 01 trial, adjuvant 
chemotherapy with S-1 showed a 5-year overall survival rate of 43.6 versus 24.2% for gem-
citabine (HR 0.60; P < 0.0001) and was relatively well tolerated [27]. These data support the 
use of S-1 as a new standard of care for adjuvant treatment among Japanese population that 
underwent surgery for pancreatic adenocarcinoma, but it should not be considered in non-
Asiatic population due to the lack of existing data.
The use of adjuvant chemotherapy can be delayed or affected by postoperative complications 
but also by the appearance of early recurrences that can be found before systemic treatment 
starts or during early image control during adjuvant treatment. Prospective observational 
trials have shown that up to 38% of resected pancreatic cancer patients did not receive chemo-
therapy due to those reasons [28, 29]. Considering the bad prognosis of this disease, despite a 
complete resection when feasible, neoadjuvant treatments have been explored, which focused 
on improving those outcomes.
6. Locally advanced and unresectable disease
Locally advanced unresectable and metastatic pancreatic cancer patients have a similar dismal 
prognosis. In case of patients with a good performance status (ECOG 0–1), they should be 
strongly considered for treatment with high-intensity palliative chemotherapy, with the aim of 
improving quality of life and overall survival. Conroy et al. showed in the PRODIGE trial that 
FOLFIRINOX regimen when compared with gemcitabine was associated with a  significative 
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better survival, with a reported median overall survival of 11.1 months versus 6.8 months, 
respectively (HR for death 0.57 (95% CI, 0.45–0.73), p < 0.001) [30]. This trial was basically con-
ducted among French population and did not include patients of 76 years or older. In patients 
with ECOG 2 and those with ECOG 0–2 older than 75 years, a lower intensity chemotherapy 
regimen like gemcitabine with or without nab-paclitaxel should be considered. Von Hoff et al. 
published in 2013 that the combination of gemcitabine and nab-paclitaxel improves overall sur-
vival compared with gemcitabine alone (median OS 8.5 vs. 6.7 months, HR 0.72, CI 0.62–0.83, 
P < 0.001) [31]. Patients older than 75 years were also included in this study. Chemotherapy 
should not be recommended in patients with a poor performance status (ECOG 3–4) due to 
lack of benefit and because a higher risk of toxicity with worsening of quality of life.
7. Neoadjuvant treatment
Regardless of the relative poor prognosis of the disease and considering that an adequate treat-
ment is the only option for surviving a pancreatic cancer, resectable and borderline resectable 
pancreatic cancer patients should be considered for curative intention treatments [32].
Theoretically, treating patients with neoadjuvant chemotherapy might favor the eradication 
of microscopic metastatic disease to obtain better results in terms of survival. It may also help 
in making a “selection” of patients to undergo surgery: if the patient presents disease progres-
sion during treatment, an unnecessary surgery could be avoided in patients that otherwise 
would have had a rapid disease progression after surgery, considering also that oncological 
surgery for pancreatic cancer is not free of morbidity and mortality [33].
A decision analysis model to assess what was the best treatment strategy for resectable pan-
creatic cancer supported the use of neoadjuvant chemotherapy showing that it provided lon-
ger survival in comparison to surgery followed by adjuvant chemotherapy [34].
Geus et al. [35] reviewed 12,857 non-metastatic pancreatic adenocarcinoma patients who 
underwent pancreatectomy and initiated adjuvant chemotherapy. Across propensity score-
matched analysis, comparing the clinical outcomes of neoadjuvant therapy versus upfront 
surgery for pancreatic cancer by stage, neoadjuvant therapy was associated with a significant 
survival benefit after matching (median survival 22.9 vs. 17.3 months; log-rank P < 0.0001) 
compared with conventional upfront surgery followed by adjuvant therapy, in stage III 
patients.
Mokdad et al. [36] reviewed the data from a cohort of 15,237 patients (National Cancer 
Database 2006–2012) with stage I–II adenocarcinoma of the head of the pancreas that were 
treated with curative intention, comparing neoadjuvant treatment (chemotherapy or chemo-
radiotherapy combination) with patients who underwent upfront resection with or without 
adjuvant treatments (chemotherapy or chemoradiotherapy combination) to evaluate the over-
all survival impact of those modalities. The authors of this manuscript showed that patients 
who had received neoadjuvant treatment had better results in terms of survival when com-
pared with patients who underwent surgery as an upfront treatment. The median survival 
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was 26 months for the neoadjuvant group and 21 months for the group who underwent sur-
gery as an upfront treatment, but also a higher pathological tumor stage, a higher incidence 
of lymph node compromise, and a lesser R0 resection in the group that did not receive neo-
adjuvant treatment were seen. A two-arms Markov model showed that the median overall 
survival was longer for the neoadjuvant cohort (22 months) in comparison with the adjuvant 
group (20 months) [37]. Despite this information that shows better outcomes in terms of sur-
vival when neoadjuvant treatments have been done, to date, there are no phase 3 randomized 
clinical trials that support the use of neoadjuvant treatments in pancreatic cancer patients. 
Most of the available data are limited to retrospective evidence or to one-arm design-prospec-
tive clinical trials [38].
In recent years, the use of systemic preoperative chemotherapy alone or in combination with 
radiation therapy has been offered to an increasing number of patients with the main inten-
tion of reducing the size of the tumor, increasing the likelihood of negative resection margins, 
and testing the effects of cytotoxic medications in vivo [39].
Phase 2 clinical trials have evaluated the use of neoadjuvant therapy for resectable and bor-
derline resectable pancreatic cancer patients, either with chemotherapy or with chemoradio-
therapy combination (Table 1).
One quarter of the patients who underwent neoadjuvant chemoradiotherapy had disease pro-
gression, and surgery was not performed. Disparities on reported results among patients who 
underwent surgery showed an R0 resection rate between 12.5 and 96% of the total resected 
patients. Patients who had progression after treatment did it mainly with distance metastasis 
(59–73%), most of them located at the liver. Local recurrence rate was seen between 0 and 25% 
according to different reports. Reported overall survivals show also differences; patients who 
only received neoadjuvant treatment with chemoradiation had reported survival between 8 
and 34 months; patients who underwent only neoadjuvant chemotherapy achieved survivals 
up to 19 months.
Chemotherapy without radiation has been explored as an option for neoadjuvant treatment 
in pancreatic cancer. A phase 2 clinical trial in the neoadjuvant setting using gemcitabine 
with or without cisplatin showed a resection rate of 54% and a median overall survival of 
28 months in resected patients [40]. Unfortunately, similar trials using gemcitabine plus cis-
platin doublet showed inferior results [41]. Due to the heterogeneity of these studies that 
included different types of patients such as resectable, borderline resectable, and unresectable 
patients at diagnosis, but also that have used different modalities of radiotherapy and dif-
ferent schedules and schemes of chemotherapy, no conclusion can be drawn regarding the 
overall impact on survival and what are the most effective chemotherapy agents or the best 
combination of chemotherapy agents for resectable pancreatic cancer.
Since 2011, after the results of PRODIGE trial, many case series with neoadjuvant FOLFIRINOX 
for locally advanced pancreatic cancer have been published, but sample sizes of most studies 
have been too small to draw definitive conclusions about the efficacy and safety of this treat-
ment approach; however, its use followed by chemoradiation as a multimodality treatment 
has shown promising results (Table 2).
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In general, according to data mainly obtained from retrospective studies with a small num-
ber of patients with disease in borderline and locally advanced stages, between 13 and 68% 
of patients could undergo surgery after neoadjuvant treatment, achieving R0 resection in a 
range of 24–100%, with a median survival that usually exceeds 20 months.
Published results of a meta-analysis that included 13 different publications, with different 
methodologies including 325 patients with locally advanced pancreatic cancer treated with 
FOLFORINOX regimen, with some of the patients that after this treatment underwent radio-
therapy or chemoradiation, showed that 28% of the patients (91 of 325 included in this analysis) 
underwent surgery with a pooled proportion of patients who achieved R0 surgery of 78% [42]. 
In this same meta-analysis, which included a total of 689 patients with different stages, as men-
tioned before, all received FOLFIRINOX; some of them underwent other therapies such as radi-
ation or radio-chemotherapy, and not all the patients treated with FOLFIRINOX as neoadjuvant 
treatment could undergo surgery, the reported median overall survival across all the studies 
was 10–32.7 months and the reported progression-free survival ranged from 3 to 20.4 months.
In a small multicenter prospective single-arm trial that included 22 borderline resectable pan-
creatic cancer patients, Katz et al. assessed the use of four cycles of neoadjuvant-modified 
Table 1. Phase II trials of patients treated with neoadjuvant therapies.
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FOLFIRINOX followed by 5.5 weeks of radiation therapy with a total dose of 50.4 Gy in 28 
fractions with concurrent capecitabine twice daily during radiation [43]. Grade 3 or higher 
toxicity was reported in 64% of patients. Fifteen patients underwent pancreatectomy, 80% 
of them required vascular resection, and R0 resection was achieved in 93% of the resected 
patients. The reached median overall survival was 21.7 months. Using another regimen of 
neoadjuvant chemotherapy, a single patient case report showed efficacy achieving R0 resec-
tion in this patient who had unresectable locally advanced diseased and was treated with 
gemcitabine plus nab paclitaxel combination followed by FOLFIRINOX before surgery [44].
To address the question if neoadjuvant treatments or adjuvant treatments will result with 
better outcomes, different prospective trials are currently ongoing, and their aim is to find 
out the real impact of the neoadjuvant treatments in resectable and borderline resectable pan-
creatic cancer patients. Those trials include neoadjuvant chemotherapy, neoadjuvant versus 












25/ 25 BR: 12 (48%), 
LA: 13 (52%)
SBRT 36 Gy 11 (44%) 7 (63%) NA
Faris/2013/
Retrospective
22/ 22 LA: 22 (100%) IMRT 50.4 Gy 12 (54.5%) 5 (42) 24.7 (19.0–30.3)
Ferrone/2015/
Retrospective
40/127 BR:15 (12%), 
LA 25(20%)
CHRT: 50.4 Gy 
and 5-FU*
40 (31.4%) 35(92) 34
Hosein/2012/
Retrospective
18/18 BR 4 (22%), LA 
14 (78%)
CHRT: 50.4 Gy 
and GEM**
10 (55.5%) 8 (80%) 32.7 (23.1-42.3)
Marthey/2015/Cohort 77/77 LA: 77 (100%) 54 Gy*** 28 (36.3%) 25 (89) 22 (12.3-29.9)
Mellon/2015/
Retrospective
21/159 BR 110 {69%), 
A: 49 (31%)
SBRT 30-40 Gy# 21 (13.2%) 5 (24) 15
Sadot/2015/
Retrospective
101/101 BR: 31 (30.6%), 
LA: 70 (69.3%)




22/22^ BR 22 (100%) CHRT 50.4 Gy^ 15 (68%) 15 (100) 21.7
Noady: neoadjuvant, BR: borderline resectable, LA: locally advanced, SBRT: stereotactic body radiosurgery, IMRT: 
intensity-modulated radiation therapy, HIGRT: hipofractionated radiation therapy, NC: not correspond, CHRT: 
chemoradiation, 5-FU: fluorouracil, GEM: gemcitabine.*After FOLFIRINOX and before surgical exploration.
**For unresectable patients post FOLFIRINOX, radiation sensitization patients received concurrent gemcitabine plus 
IMRT.
***External radiotherapy for consolidation.
#After neoadjuvant chemotherapy.
¨¨Patients who appeared to convert to resectable disease underwent surgical exploration, and patients with stable disease 
were typically initiated with chemoradiotherapy with 5-FU or GEM.
^Modified FOLFIRINOX treatment: (85 mg/m2 of oxaliplatin, 180 mg/m2 of irinotecan hydrochloride, 400 mg/m2 of 
leucovorin calcium, and then 2400 mg/m2 of 5-fluorouracil for 4 cycles) followed by 5.5 weeks of external-beam radiation 
(50.4 Gy delivered in 28 daily fractions) with capecitabine (825 mg/m2 orally twice daily) prior to pancreatectomy. 10 
patient initiated adjuvant therapy with GEM.
Table 2. FOLFIRINOX studies only with BR and LA pancreatic cancer.
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adjuvant chemotherapy, neoadjuvant chemoradiation, neoadjuvant chemoradiation versus 
upfront surgery, and other modalities as well [45–49].
Concerning toxicity among patients treated with neoadjuvant treatments that have been 
reported, mostly as local experiences or as small institutional trials, there are no clear data 
concerning side effects of neoadjuvant therapies, nor there are data on perioperative morbid-
ity and mortality, comparing patients who underwent upfront surgery and patients who 
received neoadjuvant treatment and then underwent surgery. The biggest data on quality of 
life come from reports in the metastatic setting. The quality of life report of the PRODIGE-4 
trial (mentioned earlier), FOLFIRINOX chemotherapy reduced the quality of life impairment 
compared with gemcitabine, but also it has benefit in the quality of life that can be a surrogate 
for survival, as physical functioning and some symptoms severity were prognostic factors 
for survival [50]. In a meta-analysis of FOLFIRINOX in locally advanced pancreatic cancer, 
60% of the patients presented G3 or higher side effects, neutropenia and diarrhea being the 
most frequent events among treated patients. There were no related deaths attributable to 
FOLFIRINOX [42]. In a retrospective analysis of patients undergoing FOLFIRINOX as neoad-
juvant treatment followed by surgery, Marchegiani et al. concluded that among patients who 
underwent neoadjuvant chemotherapy, there were less postoperative pancreatic fistula and 
less postoperative pancreatic hemorrhage but delayed in gastric emptying [51].
8. Current guidelines
Due to a lack of strong data based on phase 3 clinical trials, it is not possible to talk about a 
gold-standard treatment in the neoadjuvant setting for pancreatic cancer patients. Most of the 
groups support the idea to perform surgery as an upfront treatment in resectable patients fol-
lowed by adjuvant chemotherapy.
Current ESMO guidelines support the use of FOLFIRINOX followed by chemoradiotherapy 
in borderline resectable patients as a main option in pancreas cancer [52]. Contrarily, ASCO 
guidelines indicate that there is no clear evidence to support one regimen over another, and 
physicians may offer therapy based on extrapolation from data derived from studies in the 
metastatic setting [53].
Pancreatic cancer patients with resectable or borderline resectable disease should always be 
discussed in a multidisciplinary team. Neoadjuvant treatment should always be considered to 
attempt an R0 resection; otherwise, the chance of cure in non-R0-resected patients and also due 
to the meaning of the diagnosis itself will be similar to metastatic patients. Multidisciplinary 
team should at least include a digestive oncological surgeon with expertise in pancreatic sur-
gery, a medical oncologist, a radiologist with expertise in pancreas, a radiation oncologist, 
and a pathologist, given the disparity of opinions and the importance of treatment agreement 
looking forward the best chance to those patients.
At SLAGO 2015 (Latin American Gastro-Enterology Cancer Symposium) congress [54], a 
meeting held every 2 years in Latin America that focuses on digestive malignancies, specialists 
from different Latin American countries met to discuss about pancreatic cancer. Concerning 
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borderline resectable pancreatic cancer patients, SLAGO’s main recommendation is to con-
sider FOLFIRINOX schedule as the best choice for neoadjuvant treatment; then after selected 
patients that do not have disease progression after chemotherapy could be considered for 
radiotherapy with capecitabine as radio-sensibilizer before surgery. For patients who have 
contraindication to receive FOLFIRINOX and in older than 76 years, neoadjuvant treatment 
with gemcitabine plus nab paclitaxel combination can be an option [55].
9. Conclusions
Pancreatic cancer is one of the most lethal malignancies among all types of solid tumors. 
Most of the patients are diagnosed at unresectable or at advanced stages with no chances of 
cure. Early diagnosis is critical to give the patient the chance of cure; however, most of the 
patients are diagnosed where the tumor is not amenable to be resected. Even more, many of 
the patients who will undergo an R0 resection will relapse before 2 years after surgery.
We would like to remark that there is no strong evidence to make final conclusions in order to 
define the best upfront treatment in non-metastatic resectable and borderline resectable pan-
creatic cancer patients. For resectable patients at diagnosis, upfront surgery is still the standard 
of care followed by adjuvant chemotherapy. In this subgroup of patients, radiotherapy and 
chemoradiotherapy do not seem to be the best choice. On the other hand, neoadjuvant chemo-
therapy has not been explored yet in well-designed clinical trials, and its use has been just lim-
ited to small experiences. Borderline resectable pancreatic cancer patients are a subgroup where 
upfront surgery has a low chance of achieving an R0 resection; therefore, these patients must be 
considered to receive neoadjuvant treatments in order to improve complete tumor resection and 
as a consequence to improve survival. As in the resectable subset of patients, radiotherapy or 
chemoradiotherapy has not shown a real impact in this group. FOLFIRINOX followed or not by 
chemoradiotherapy seems to be the best option to improve resectability, for achieving complete 
resection and pathological downstaging and for improving overall survival in resected patients. 
Final reports from clinical trials will set the key whether or not neoadjuvant treatment, in resect-
able and borderline resectable pancreatic cancer patients, should be mandatory or recommended.
Author details
Christian Caglevic Medina1*, Sergio Panay Serra2, Carlos Gallardo Araneda A3, 
Jaime Anabalon Toha2, Elizabeth Milla Ramirez2 and Mauricio Mahave Caceres3
*Address all correspondence to: oncodemia@yahoo.com; caglevicc@falp.org
1 Oncólogo Médico, Clínica Alemana Santiago, Santiago, Chile
2 Medical Oncology Department, Fundacion Arturo Lopez Perez, Santiago, Chile
3 Unit of Investigational Cancer Drugs, Medical Oncology Department, Fundacion Arturo 
Lopez Perez, Santiago, Chile




[1] AJCC Cancer Staging Manual. 7th ed. Springer; 2010;3:285-296
[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians. 
2016;66(1):7-30
[3] Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, 
Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER 
Cancer Statistics Review, 1975-2014. Bethesda, MD: National Cancer Institute. [https://
seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted 
to the SEER web site] April 2017
[4] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A 
Cancer Journal for Clinicians; 2011 Mar-Apr;61(2):69-90
[5] Vallebouna C. Primer Informe de Registros Poblacionales de Cáncer de Chile Quin-
quenio 2003-2007. MINSAL; 2012. https://www.paho.org/chi/index.php?option=com_ 
docman&view=download&alias=174-informe-rpc-chile-2003-2007&category_slug= 
cancer&Itemid=1145. Accessed February 15, 2018
[6] Karanikas M, Esempidis A, et al. Pancreatic cancer from molecular pathways to treat-
ment opinion. Journal of Cancer. 2016;7(10):1328-1339
[7] Feng M, Xiong G, Cao Z, et al. PD-1/PD-L1 and immunotherapy for pancreatic cancer. 
Cancer Letters. 2017 Oct 28;407:57-65. DOI: 10.1016/j.canlet.2017.08.006. Epub 2017 Aug 18
[8] Klein AP, Hruban RH, Brune KA, et al. Familial pancreatic cancer. Cancer Journal. 
2001;7:266-273
[9] Jacobs EJ, Chanock SJ, Fuchs CS, et al. Family history of cancer and risk of pancreatic 
cancer: A pooled analysis from the pancreatic cancer cohort consortium (PanScan). 
International Journal of Cancer. 2010;127:1421-1428
[10] Moran A, O’Hara C, Khan S, et al. Risk of cancer other than breast or ovarian in indi-
viduals with BRCA1 and BRCA2 mutations. Familial Cancer. 2012;11:235-242
[11] Peterlongo P, Catucci I, Pasquini G, et al. PALB2 germline mutations in familial breast 
cancer cases with personal and family history of pancreatic cancer. Breast Cancer 
Research and Treatment. 2011;126:825-828
[12] McWilliams RR, Wieben ED, Rabe KG, et al. Prevalence of CDKN2A mutations in pan-
creatic cancer patients: Implications for genetic counseling. European Journal of Human 
Genetics. 2011;19:472-478
[13] Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carci-
noma correlates with patterns of failure in patients with pancreatic cancer. Journal of 
Clinical Oncology. 2009;27:1806-1813
[14] Hruban RH, Petersen GM, Ha PK, et al. Genetics of pancreatic cancer: From genes to 
families. Surgical Oncology Clinics of North America. 1998;7:1-23
Advances in Pancreatic Cancer190
[15] Yurgelun MB. Germline testing for individuals with pancreatic cancer: The benefits and 
challenges to casting a wider net. Journal of Clinical Oncology. 2017;35:3375
[16] Beger HG, Rau B, Gansauge F, et al. Treatment of pancreatic cancer: Challenge of the 
facts. World Journal of Surgery. 2003;27:1075-1084
[17] Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, et al. Potentially curable 
pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. 
Journal of Clinical Oncology. 2016;34(21):2541-2556
[18] Whipple A. Present day surgery of the pancreas. The New England Journal of Medicine. 
1942;226:515-518
[19] Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, et al. Pancreatic duc-
tal adenocarcinoma: Long-term survival does not equal cure. Surgery. 2012;152(Suppl 1): 
S43-S49
[20] Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection 
for ductal adenocarcinoma of the pancreas. Is it really improving? Annals of Surgery. 
1995;221(1):59-66
[21] Evans DB, Farnell MB, Lillemoe KD, et al. Surgical treatment of resectable and borderline 
resectable pancreas cancer: Expert consensus statement. Annals of Surgical Oncology. 
2009;16:1736
[22] Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, et al. Adjuvant chemotherapy with 
gemcitabine vs observation in patients undergoing curative-intent resection of pancre-
atic cancer: A randomized controlled trial. JAMA. 2007;297(3):267-277
[23] Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant 
radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and 
periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer coopera-
tive group. Annals of Surgery. 1999;230(6):776-782
[24] Garofalo M, Regine W, MD TM. On statistical reanalysis, the EORTC trial is a positive trial 
for adjuvant chemoradiation in pancreatic cancer. Annals of Surgery. 2006;244(2):332-333
[25] Morganti AG, Falconi M, van Stiphout RG, Mattiucci GC, Alfieri S, Calvo FA, et al. 
Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer. 
International Journal of Radiation Oncology, Biology, Physics. 2014;90(4):911-917
[26] Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, 
O’Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, 
Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, 
McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, 
Hackert T, Jackson R, Büchler MW, European Study Group for Pancreatic Cancer. 
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy 
in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, ran-
domised, phase 3 trial. Lancet. 2017 Mar 11;389(10073):1011-1024
Neoadjuvant Treatment for Nonmetastatic Pancreatic Cancer
http://dx.doi.org/10.5772/intechopen.75739
191
[27] Uesaka K et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancre-
atic cancer. Lancet. 2016;388:248-257
[28] Tzeng CW, Tran Cao HS, Lee JE, Pisters PW, Varadhachary GR, et al. Treatment sequenc-
ing for resectable pancreatic cancer: Influence of early metastases and surgical compli-
cations on multimodality therapy completion and survival. Journal of Gastrointestinal 
Surgery. 2014;18(1):16-24
[29] Aloia TA, Lee JE, Vauthey JN, Abdalla EK, Wolff RA, et al. Delayed recovery after pan-
creaticoduodenectomy: A major factor impairing the delivery of adjuvant therapy? 
Journal of the American College of Surgeons. 2007;204(3):347-355
[30] Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic 
pancreatic cancer. The New England Journal of Medicine. 2011;364:1817-1825
[31] Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, 
Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, 
Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. 
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. The New 
England Journal of Medicine. 2013 Oct 31;369(18):1691-1703
[32] Caglevic C, Panay S, Reyes FC, Rolfo C, Mahave M. Is neoadjuvant an option for the 
treatment of non metastatic pancreatic cancer patients? Journal of Pancreatic Research, 
Disorders & Therapy. 2017;1(1):00003
[33] Winner M, Goff SL, Chabot JA. Neoadjuvant therapy for nonmetastatic pancreatic duc-
tal adenocarcinoma. Seminars in Oncology. 2015;42(1):86-97
[34] VanHouten JP, White RR, Jackson GP. A decision model of therapy for potentially resect-
able pancreatic cancer. The Journal of Surgical Research. 2012;174:222-230
[35] De Geus SW, Evans DB, Bliss LA, Eskander MF, Smith JK, Wolff RA, Miksad RA, 
Weinstein MC, Tseng JF. Neoadjuvant therapy versus upfront surgical strategies in 
resectable pancreatic cancer: A Markov decision analysis. European Journal of Surgical 
Oncology. 2016;42:1552-1560
[36] Mokdad Ali A, Minter Rebeca M, Zhu H, Augustine MM, Porembka MR, et al. 
Neoadjuvant therapy followed by resection versus upfront resection for resectable 
pancreatic cancer: A propensity score matched analysis. Journal of Clinical Oncology. 
2017;35(5):515-522
[37] Sharma G, Whang EE, Ruan DT, Ito H. Efficacy of neoadjuvant versus adjuvant ther-
apy for resectable pancreatic adenocarcinoma: A decision analysis. Annals of Surgical 
Oncology. 2015;22(Suppl 3):S1229-S1237
[38] Gillen S, Schuster T, Meyer ZumBuschenfelde C, Friess H, Kleeff J. Preoperative/neoad-
juvant therapy in pancreatic cancer: A systematic review and meta-analysis of response 
and resection percentages. PLoS Medicine. 2010;7(4):e1000267
[39] Sutton JM, Abbott DE. Neoadjuvant therapy for pancreas cancer: Past lessons and future 
therapies. World Journal of Gastroenterology. 2014;20:15564-15579
Advances in Pancreatic Cancer192
[40] Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, et al. A randomized 
phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: Gemcitabine 
alone versus gemcitabine combined with cisplatin. Annals of Surgical Oncology. 2007; 
14(7):2088-2096
[41] Heinrich S, Pestalozzi BC, Schäfer M, Weber A, Bauerfeind P, et al. Prospective phase 
II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable 
adenocarcinoma of the pancreatic head. Journal of Clinical Oncology. 2008;26(15): 
2526-2531
[42] Suker M et al. FOLFIRINOX for locally advanced pancreatic cancer. The Lancet 
Oncology. 2016;17:801-810
[43] Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, et al. Preoperative modified 
FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline 
resectable pancreatic cancer: Alliance for clinical trials in oncology trial A021101. JAMA 
Surgery. 2016;151(8):e161137
[44] Kunzmann V, Herrmann K, Bluemel C, Kapp M, Hartlapp I, et al. Neoadjuvant chemo-
therapy with nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in a patient 
with locally advanced unresectable pancreatic cancer. Case Reports in Oncology. 
2014;7(3):648-655
[45] Adjuvant versus neo-adjuvant plus adjuvant chemotherapy in resectable pancreatic can-
cer. ClinicalTrials.gov NCT01314027
[46] Gemcitabine, cisplatin, epirubicin, and capecitabine in treating patients with stage I-II 
resectable pancreatic cancer (PACT15). ClinicalTrials.gov. NCT01150630
[47] Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoad-
juvant/adjuvant FOLFIRINOX for resectable pancreas carcinoma. ClinicalTrials.gov. 
NCT02172976
[48] Neoadjuvant S-1 and concurrent radiotherapy for borderline resectable pancreatic can-
cer. ClinicalTrials.gov NCT02459652
[49] Versteijne E, van Eijck CH, Punt CJ, Suker M, Zwinderman AH, Dohmen MA, 
Groothuis KB, Busch OR, Besselink MG, de Hingh IH, Ten Tije AJ, Patijn GA, Bonsing BA, 
de Vos-Geelen J, Klaase JM, Festen S, Boerma D, Erdmann JI, Molenaar IQ, van der 
Harst E, van der Kolk MB, Rasch CR, van Tienhoven G; Dutch Pancreatic Cancer Group 
(DPCG). Preoperative radiochemotherapy versus immediate surgery for resectable and 
borderline resectable pancreatic cancer (PREOPANC trial): Study protocol for a multi-
centre randomized controlled trial. Trials. 2016 Mar 9;17(1):127
[50] Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouché O, Guimbaud R, 
Bécouarn Y, Adenis A, Raoul JL, Boige V, Bérille J, Conroy T. Impact of FOLFIRINOX 
compared with gemcitabine on quality of life in patients with metastatic pancreatic 
cancer: Results from the PRODIGE 4/ACCORD 11 randomized trial. Journal of Clinical 
Oncology. 2013 Jan;31(1, 1):23-29
Neoadjuvant Treatment for Nonmetastatic Pancreatic Cancer
http://dx.doi.org/10.5772/intechopen.75739
193
[51] Marchegiani G, Andrianello S, Nessi C, Sandini M, Maggino L, Malleo G, Paiella S, 
Polati E, Bassi C, Salvia R. Neoadjuvant therapy versus upfront resection for pancreatic 
cancer: The actual spectrum and clinical burden of postoperative complications. Annals 
of Surgical Oncology. 2018 Mar;25(3):626-637
[52] Ducreux M, Cuhna A, Caramella C, Hollebecque A, Burtin P, et al. Cancer of the pan-
creas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals 
of Oncology. 2015;26(Suppl 5):v56-v68
[53] Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, 
Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB III, 
Urba S, Yee NS. Locally advanced, unresectable pancreatic cancer: American Society 
of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. August 
2016;34(22):2654-2668
[54] Caglevic C, Gallardo J, San Martín ME. Latin American symposium on oncological gas-
troenterology. Ecancer Medical Science. 2013;7:ed23
[55] Caglevic C, Gallardo J, de la Torre M, Mahave M, Müller B, et al. Recomendaciones sobre 
el manejo del cáncer de páncreas tipo adenocarcinoma en Latinoamérica. Reunión del 
Consenso del Simposio Latinoamericano de Gastroenterología Oncológica (SLAGO) y 
de la Asociación Ibero Latinoamericana de Terapia Radiante (ALATRO), Viña del Mar, 
Chile 2015. Revista Médica de Chile. 2015;144(10):1305-1318
Advances in Pancreatic Cancer194
